Research programme: dipiperidine anti-infectives/anti-inflammatories - Sequella

Drug Profile

Research programme: dipiperidine anti-infectives/anti-inflammatories - Sequella

Alternative Names: SQ 609

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sequella
  • Class Adamantanes; Piperidines; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Crohn's disease; Severe acute respiratory syndrome; Tuberculosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in USA (PO)
  • 24 Sep 2012 SQ 609 is available for licensing as of 24 Sep 2012. http://www.sequella.com/
  • 12 Sep 2012 SQ 609 is still in Preclinical trials for Tuberculosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top